PDCD1 and neoplasm: The commonly used inhibitors against a variety of tumour types consist of therapeutic monoclonal antibodies, such as pembrolizumab and ipilimumab, targeting the IC pathways of programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), respectively.